SciClone Pharmaceuticals, Inc. (SCLN) news stock charts
SciClone Pharmaceuticals, Inc. (SCLN) Investment Summary:
SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. We are positioned to grow our two assets, a biotechnology business focused on developing late-stage products for cancer and viral infectious diseases for the United States and Europe, and SciClone China, our pharmaceutical business which generates important cash flow to fund its growth and significantly contributes to the funding of our biotechnology business. Our strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and the People’s Republic of China, one of the world’s fastest growing pharmaceutical markets. Our lead product ZADAXIN®, our brand of thymalfasin, is approved in select international markets and is one of the largest selling imported drugs in China today, measured in revenue. For the U.S. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001193125-08-055606.html#FIS_BUSINESS"www.sciclone.com
Founded in 1989
SCICLONE PHARMACEUTICALS INC (SCLN:NASDAQ)
LAST $3.69 USD
CHANGE TODAY -0.06 -1.60%
VOLUME 50.8K
As of 9:42 AM 03/22/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of SCICLONE PHARMACEUTICALS INC (SCLN)
|
OPEN
$3.70
|
PREVIOUS CLOSE
$3.75
|
|
|
DAY HIGH
$3.71
|
DAY LOW
$3.65
|
|
|
52 WEEK HIGH
09/1/09 - $5.33
|
52 WEEK LOW
03/23/09 - $1.21
|
|
|
MARKET CAP
174.6M
|
AVERAGE VOLUME 10 D
589.4K
|
|
|
EPS TTM
$0.25
|
SHARES OUTSTANDING
47.3M
|
|
|
SCLN Does Not Pay Dividends
|
P/E TTM
14.8x
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for SCICLONE PHARMACEUTICALS INC (SCLN)
SciClone Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 16, 2010).
03/16/2010
SciClone Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 16, 2010).
SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009; Provides Earnings Guidance for the Year 2010
03/2/2010
SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2009 grew to $18.1 million, or 18% compared to the fourth quarter of 2008. Net income was $2.4 million or $0.05 per share, compared with a net loss of $3.1 million or $0.07 per share in the fourth quarter of 2008, both on a basic and diluted basis. Income from operations was $2,596,000 against loss from operations of $3,062,000 for the same period of the last year. Income before provision for income tax was $2,613,000 against loss before provision for income tax of $3,009,000 for the same period of the last year. For the year ended December 31, 2009, total revenues increased by 34% to $72.4 million, compared with revenues of $54.1 million for the year ended December 31, 2008. Net income was $11.9 million, or $0.26 and $0.25 per dilutedshare on a basic and diluted basis, respectively, compared with a net loss of $8.3 million or $0.18 per share for the year ended December 31, 2008, both on a basic and diluted basis. Income from operations was $12,594,000 against loss from operations of $8,434,000 for the same period of the last year. Income before provision for income tax was $12,586,000 against loss before provision for income tax of $7,873,000 for the same period of the last year. The company anticipates 2010 revenues of between $82 and $85 million, an increase of approximately 15% over 2009. SciClone expects its revenue growth to be driven by the sales of ZADAXIN, principally to China. The Company also anticipates earnings per share for the full year 2010 to be between $0.31 and $0.35.
SciClone Pharmaceuticals, Inc. to Report Q4, 2009 Results on 03/02/2010
02/18/2010
SciClone Pharmaceuticals, Inc. announced that they will report Q4, 2009 results on 03/02/2010
SciClone Pharmaceuticals, Inc. financial resources
SCLN Competitors
| Company | Last | Change |
| Access Pharmaceuticals Inc | $2.46 USD | -0.13 |
| InterMune Inc | $40.67 USD | -0.11 |
| Migenix Inc | C$0.06 CAD | 0.00 |
| Vertex Pharmaceuticals Inc | $42.62 USD | -0.105 |
| XenoPort Inc | $8.69 USD | -0.07 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | SCLN | Industry Range |
| Price/Earnings | 14.9x |
|
| Price/Sales | 2.4x |
|
| Price/Book | 3.3x |
|
| Price/Cash Flow | 14.9x |
|
| TEV/Sales | 2.0x |
|
|
SCLN |
||
|
SCLN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About SciClone Pharmaceuticals, Inc.
SCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
2010-03-17 03:26:24
Quote: See "Note Regarding Forward-Looking Statements" and
"Risk Factors" contained in this Annual Report on Form 10-K.
Overview
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty
pharmaceutical company with a substantial international business, based
primarily in the People's Republic of China ("China"), and with a product
portfolio of novel therapies for cancer and infectious diseases. Our strategy is
focused on international sales growth, a ...Read article
SciClone Pharma reports 4Q profit on sales
2010-03-08 03:41:06
Quote: NEW YORK (AP) -- SciClone Pharmaceuticals Inc. reported a fourth-quarter profit on higher sales of the vaccine booster Zadaxin and lower costs.The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.For the full year, SciClon...Read article
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
2010-03-08 03:41:06
Quote: Read article
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
2010-03-03 01:12:12
Quote: Press ReleaseSource: SciClone Pharmaceuticals, Inc.On Monday March 1, 2010, 4:30 pm ESTFOSTER CITY, CA--(Marketwire - 03/01/10) - SciClone Pharmaceuticals, Inc. (NASDAQ: - To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at SciClone Pharmaceuticals (NASDAQ: - ) is a profit-focused, global
specialty pharmaceutical company with a substantial international business,
based primarily in the People's Re...Read article
UPDATE - SciClone Q4 beats Street; forecasts 2010 EPS above view
2010-03-03 01:12:11
Keywords: Pharmaceuticals (sub-industry),United States of America,Healthcare facilities,Commercial services and supplies (industry group),Industrial machinery,Machinery,Corporate Results,Corporate Results Forecasts,Healthcare,Healthcare services,Healthcare provider
Quote: UPDATE 1-SciClone Q4 beats Street; forecasts 2010 EPS above view
* Q4 EPS $0.05 vs est $0.02 * Q4 revenue $18.1 mln vs est $18.0 mln * Sees 2010 EPS $0.31-$0.35 vs est $0.29 * Backs 2010 rev outlook of $82-$85 mln * Shares up 6 pct in after-mkt trade March 2 (Reuters) - SciClone Pharmaceuticals Inc (SCLN.O)
posted a better-than-expected quarterly profit, helped by
strong sales of its hepatitis B treatment Zadaxin in China, and
forecast fiscal 2010 earnings above analysts' expectations. Fourth-q...Read article
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
2010-03-03 01:12:11
Quote: Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On February 25, 2009, based upon the recommendation of the Compensation
Committee as part of its annual compensation review, the Board of Directors of
SciClone Pharmaceuticals, Inc., a Delaware corporation (the "Company") approved
the grant of the following options (the "Options") to purchase shares of the
Company's com...Read article
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
2010-03-03 01:12:11
Quote: Read article
SciClone Pharma reports 4Q profit on sales
2010-03-03 01:12:10
Quote: NEW YORK (AP) -- SciClone Pharmaceuticals Inc. reported a fourth-quarter profit on higher sales of the vaccine booster Zadaxin and lower costs.The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.For the full year, SciClon...Read article
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
2010-03-02 07:34:31
Quote: Press ReleaseSource: SciClone Pharmaceuticals, Inc.On Monday March 1, 2010, 4:30 pm ESTFOSTER CITY, CA--(Marketwire - 03/01/10) - SciClone Pharmaceuticals, Inc. (NASDAQ: - To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at SciClone Pharmaceuticals (NASDAQ: - ) is a profit-focused, global
specialty pharmaceutical company with a substantial international business,
based primarily in the People's Re...Read article
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
2010-03-01 06:10:48
Quote: Interestedparties who wish to listen to the webcast should visit the InvestorRelations section of SciClone's website at SciClone Pharmaceuticals (NASDAQ:- ) is a profit-driven, globalspecialty pharmaceutical company with a substantial internationalbusiness and a product portfolio of novel therapies for cancer andinfectious diseases. SciClone is focused on continuing internationalsales growth, a cost-containing clinical development strategy, andoverall expense management. ZADAXIN (thymalfasin or ...Read article
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
2010-02-19 04:29:32
Quote: Interestedparties who wish to listen to the webcast should visit the InvestorRelations section of SciClone's website at SciClone Pharmaceuticals (NASDAQ:- ) is a profit-driven, globalspecialty pharmaceutical company with a substantial internationalbusiness and a product portfolio of novel therapies for cancer andinfectious diseases. SciClone is focused on continuing internationalsales growth, a cost-containing clinical development strategy, andoverall expense management. ZADAXIN (thymalfasin or ...Read article
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
2010-02-16 06:40:29
Quote: Read article
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
2010-02-16 06:40:29
Quote: Press ReleaseSource: SciClone Pharmaceuticals, Inc.On Tuesday February 2, 2010, 6:00 am ESTFOSTER CITY, CA--(Marketwire - 02/02/10) - SciClone Pharmaceuticals, Inc. (NASDAQ: - To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at SciClone Pharmaceuticals (NASDAQ: - ) is a profit-driven, global
specialty pharmaceutical company with a substantial international business
and a product portfolio of novel...Read article
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
2010-02-09 07:16:18
Quote: Read article
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
2010-02-03 01:28:29
Quote: Press ReleaseSource: SciClone Pharmaceuticals, Inc.On Tuesday February 2, 2010, 6:00 am ESTFOSTER CITY, CA--(Marketwire - 02/02/10) - SciClone Pharmaceuticals, Inc. (NASDAQ: - To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at SciClone Pharmaceuticals (NASDAQ: - ) is a profit-driven, global
specialty pharmaceutical company with a substantial international business
and a product portfolio of novel...Read article
SciClone drug strengthens swine flu shot in tests
2010-01-13 03:09:47
Quote: (AP) -- SciClone Pharmaceuticals Inc. said Tuesday that early results from a clinical trial show its vaccine booster Zadaxin improves the effectiveness of a swine flu shot.SciClone, based in Foster City, Calif., and its partner Sigma-Tau SpA, based in Rome, said subjects who were injected with Zadaxin and Novartis AG's swine flu vaccine Focetria were more likely to have an immune response to the vaccine than those who received Focetria alone.SciClone's stock advanced 31 cents, or 11 percent, to ...Read article
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
2010-01-13 03:09:47
Quote: Read article
UPDATE - SciClone says adjuvant raises H1N1 vaccine response
2010-01-13 03:09:46
Keywords: Pharmaceuticals (sub-industry),United States of America,Switzerland,Western Europe,Europe,Central and Eastern Europe,Company News item,Economic news, EC, business/financial pages,
Quote: UPDATE 1-SciClone says adjuvant raises H1N1 vaccine response
* Zadaxin when used with Novartis vaccine raises immunity * Shares up as much as 14 pct(Adds analyst comments, updates share movement) By Anand Basu BANGALORE, Jan 12 (Reuters) - SciClone Pharmaceuticals Inc
(SCLN.O) said its adjuvant, Zadaxin, in combination with
Novartis' (NOVN.VX) H1N1 vaccine increased immune response,
sending SciClone's shares up as much as 14 percent. An adjuvant is an ingredient that boosts the immune-system
res...Read article
SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance
2010-01-12 03:30:59
Quote: Read article
UPDATE - SciClone forecasts '10 rev above mkt view
2010-01-12 03:30:58
Keywords: Corporate Results Forecasts,Healthcare,Pharmaceuticals and biotechnology,United States of America,Pharmaceuticals (sub-industry),Business activities,Corporate Results,Company News item,Economic news, EC, business/financial pages,
Quote: UPDATE 1-SciClone forecasts '10 rev above mkt view* Sees '10 rev $82-$85 mln vs est $73.6 mln * Backs '09 EPS view of $0.18-$0.22 * Sees '09 rev at $72.4 mln vs est $72.3 mln Jan 11 (Reuters) - SciClone Pharmaceuticals Inc (SCLN.O)
gave a better-than-expected 2010 revenue outlook driven by its
strong international commercial operations. In a regulatory filing, the company backed its previous
earnings view of 18 cents to 22 cents a share for 2009, and
forecast revenue at $72.4 million. Analysts o...Read article
Would you like to leave a comment about SciClone Pharmaceuticals, Inc. SCLN
Find out what social network information about SciClone Pharmaceuticals, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides SciClone Pharmaceuticals, Inc.'s Stock there is more great penny stock and market information at Realpennies